News Category
Catherine Cifuentes-Rojas releases a free early-stage go/no-go checklist for biotherapeutics teams to help them make data-driven decisions and avoid c...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its investigational progressive MS drug Lucid-MS toward Phase 2 im...
Annovis Bio CEO Maria Maccecchini will present at two November conferences, highlighting the company's clinical programs and upcoming milestones for i...
NanoViricides' Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo is progressing, with Phase IIB anticipated, offering a potential oral treat...
A mutated flu virus spreading early on the West Coast has prompted urgent vaccination calls and highlighted the role of decentralized testing tools fr...
Tonix Pharmaceuticals' Phase 3 RELIEF and RESILIENT studies demonstrate that TONMYA significantly improves pain, symptom severity, and physical functi...
Tonix Pharmaceuticals will report third-quarter 2026 financial results on Nov. 9, giving investors a key update on the commercial rollout of its newly...
Annovis Bio will present three buntanetap-focused sessions at the 2026 CTAD conference, highlighting its mechanism, pivotal Phase 3 trial design, and ...
NeuroThera Labs has completed manufacturing and obtained European QP batch release certification for its SCI-110 investigational drug, enabling shipme...
BioVersys published Phase 1 data showing BV100 achieves high lung penetration and has a milder drug-interaction profile than rifampicin, bolstering th...
Quantum BioPharma's Unbuzzd clinical trial results were highlighted in Men's Fitness, drawing attention to the company's alcohol recovery formulation ...
NanoViricides reports positive juvenile animal safety results for its broad-spectrum antiviral NV-387, potentially enabling pediatric clinical trials ...
Quantum BioPharma's Unbuzzd alcohol recovery formulation gained mainstream attention through a Men's Fitness article, but the mixed clinical trial res...
Tonix Pharmaceuticals will present new data on its recently approved fibromyalgia drug TONMYA at the 2026 IASP World Congress on Pain, highlighting th...
New research shows that measles can cause lasting immune damage, making survivors more susceptible to other infections, underscoring the importance of...
Tonix Pharmaceuticals will present its TNX-801 vaccine platform at the World Vaccine Congress Europe, highlighting its potential to address mpox and o...
OrthodontiCell has secured sufficient capital to complete remaining testing for its planned U.S. Phase II pivotal study of bioelectric technology aime...
hyperCORE International's new leadership team will guide the strategic scaling platform as it helps clinical research site networks grow while offerin...
Quantum BioPharma receives FDA clearance to begin Phase 2 testing of Lucid-MS, a non-immunological approach to multiple sclerosis that could offer a n...
The American Heart Association selected five finalists for its 2026 Health Tech Competition to accelerate innovations in cardiovascular and brain heal...
NanoViricides reports progress in its Phase IIA trial of NV-387 Oral Gummies for Ebola Bundibugyo virus in the DRC, with plans to move to a Phase IIB ...
Nutriband's $1.75 million warrant exercise provides crucial funding for the clinical development and FDA submission of its abuse-deterrent fentanyl pa...
Leksum LLC's agreement with the Medical University of Vienna to prepare for Phase I/II trials of LK-ICU highlights a promising biologic therapy that c...
The American Heart Association has launched a tiered portfolio of cardiovascular-kidney-metabolic education, from 15-minute micro-learnings to impleme...
Newron Pharmaceuticals is reviewing FDA feedback on a clinical hold at U.S. sites of its Phase 3 ENIGMA-TRS 2 study while enrollment continues outside...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to execute a Phase 2 trial of Lucid-MS, a nove...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher's clinical research business to implement a Phase 2 trial of Lucid-MS, a fi...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel Lucid-MS treatment for progressive multiple sclerosis in...
XORTX Therapeutics is developing XORLO, a novel gout treatment, and aims to submit a New Drug Application to the FDA next year, potentially addressing...
Quantum BioPharma has entered a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, a first-in-class neuropr...
NanoViricides' upcoming presentation at the NIBA 153rd Investment Conference will spotlight its broad-spectrum antiviral NV-387, currently in Phase 2 ...
Quantum BioPharma's Study Start-Up Agreement with Thermo Fisher Scientific marks a critical step toward launching a Phase 2 trial for its novel multip...
Okogen, Inc. has received authorization from India's CDSCO to advance its EMERALD Phase 1/2 study of Treyegen™ (OKG-0303) for acute infectious conjunc...
NanoViricides' NV-387 oral gummies enter Phase II trials for Bundibugyo Ebola, offering a potentially deployable treatment for resource-limited settin...
Nutriband Inc. celebrates its fifth anniversary on the Nasdaq Capital Market with a shareholder letter outlining milestones and future plans for its a...
Gianluca Cerri, MD, proposes a personal policy requiring same-shift medication-assisted treatment conversations for opioid use disorder patients in ru...
Incannex Healthcare has moved its lead candidate IHL-42X into active clinical execution with the first patient dosed in the DReAMzz trial, a key step ...
A new novel by AAG Zacheriel uses fiction to examine the critical issue of clinical trial data integrity and its implications for patient safety and p...
Quantum BioPharma's Lucid-MS is advancing to a Phase 2 trial in multiple sclerosis while its unbuzzd(TM) product offers a potential royalty stream of ...
Quantum BioPharma's Lucid-MS multiple sclerosis drug enters Phase 2 testing while the company holds a 7% royalty on unbuzzd sales, signaling potential...
A new NFID survey shows high support for vaccines but widespread uncertainty about which respiratory vaccines to get, leading to low uptake and missed...
NanoViricides' fiscal 2026 results highlight regulatory approvals for Phase II trials of NV-387 in Mpox and Ebola, FDA designations for measles, and a...
NanoViricides has launched patient enrollment and dosing in a Phase II clinical trial of NV-387 Oral Gummies for Bundibugyo Ebolavirus in the Democrat...
The FDA's approval of Quantum BioPharma's IND application for Lucid-MS allows the company to begin Phase 2 clinical testing, potentially offering a ne...
Nutriband Inc. (NASDAQ: NTRB) has appointed former Navy SEAL Robert J. O'Neill to its Advisory Board, a strategic move to bolster the company's develo...
Creative Biolabs has introduced a comprehensive suite of therapeutic antibody engineering services that addresses immunogenicity, efficacy, and develo...
FamiCord AG's CDMO division Bramble Bio has signed a manufacturing agreement with VERIGRAFT AB to produce P-TEV, a personalized tissue-engineered vein...
The FDA's approval of Quantum BioPharma's IND application for Lucid-MS marks a critical step toward a novel multiple sclerosis treatment with a unique...
